Member Info for pomander

Alq- no apologies necessary, but by your reckoning with the FDA submission at least 3 years and 4 months away at the earliest and more like > 4 years away - that is going some explaining to shareholders and indeed Mr Mellon alike! Don't suppose there is a small chance that you have missed something as if true it would be a balls up of gigantium proportions and more than just contrary to the company presentations. I am not sure why you choose to use the term delay, unless to further batter management over the head with your stick, as it appears to be the timetable laid out, with FDA approval estimate in Q4/19. If that changes then sure it is then a delay to the original time frame but that is not that unusual in the big wide world of Pharma which tends to go hand in hand with delays. I concede that I would have expected some feedback on the Part 1 read out, perhaps its been delayed !!! Anyway I understand an update should be forthcoming before the end June.

How can you be aware of something that is yet to exist ?

Osakobe- I checked with MorningStar a couple of days ago - your link to the BSG website was last updated on the 18th Jan! Post buy back. I will check again. I wonder if they have done a number on JM, offered him liquidity to sell into via the buyback with with something up their sleeve.

Alq- I am sorry but sometimes your choice of language is highly confusing. The inference from your original post was that until the first patient was dosed the FDA submission was dead in the water until that happened. You then indicated that it was possible that the FDA submission was dependant upon signing up a marketing partner. Furthermore, whilst there may well be, how do you know with such certainty that there even is a delay to presentation time frames ? I am sure Dr Mike and the external consultants have matters in hand. Anyway for those that are interested BILL is yup 45% on the week.

As the record shows, I was suggesting that people buy back in 2017 - oddly from what I can see Jim Mellon sold out into the buyback - he is no longer listed a major holder. Must of been organised for himself

Alq- if advancing the FDA approval or as you infer even seriously commencing the process a marketing partner were needed to be place that renders the company presentations and other announcements made by JG and Dr Mike at the Master Investor as extremely mis-leading. I seem to recall a figure of $5 m to complete the FDA submission which is well within RP's capability. I don't think JM would sit back either without making a loan if funds were required so I ma not sure there is anything in that argument. The argument that RP is doing nothing, including addressing matters you have raised until it finds a partner just does not add up. It all gets too technical for me, but being a simple guy when you say a single person has yet to be dosed for a pivotal study, if that is a pre-requisite to securing FDA approval then I would like to know why? You have largely answered your own question about a Chinese Pharma waiting in the wings - as I said I am just speculating on both a takeover and why it has yet to happen. It is odd that no US marketing partner has yet to be found, particulalrly given the so called ''independent sales analysis'' in the presentation, even if 25% correct - unless it is RP that is holding up things, which I appreciate would be unusual.

Piltickj- surely if you had the only system on the planet that can operate at 1200 C you would at last patent protect it ? KA can claim all he likes, but clearly no one believes him and that's why Phe is worth peanuts. Its also only been tested on tyre crumble - check out what it takes to get to tyre crumble - hardly a clean process Keep denying the obvious at you own peril.

Kerno - let me provide you and without any bias with the real answer to your question as to why a major player has not snapped up Phe for pocket change - indeed a multiple of 10x todays price, which I suspect most investors would accept gladly would still represent petty cash to a major player. Firstly, the Moustetrap has no protection, it can very easily be copied , secondly it is still far from proven as being commercially viable and thirdly if anyone beleives Phe is the only company to perfect high temp gasification with its limited resources and lack of expertise in comparison to the big boys, then you are deluding yourself. Right now Phe is knocking around with connected compansies that have no capital, no track record, no employees and no hope. That's why Phe is of no interest to the majors.

Too deep for me Bignose - but I note that the date of celebration in HK varies from year to year. I guess that's to do with the Chinese lunar calendar. Anyway you had better go and fish him out of the bathtub before he gose all wrinkly.

Alq- my earleir post was withdrawn for some reason so I will tone down. If your assertion is correct that not a single person has been dosed for a pivotal study and that this is crtical to advance the FDA submission, than that is akin to saying in plain English that that RP are not actively seeking FDA approval ? How do you find information about this? I don't think India is a good benchmark for other terriritories so respectfully I believe your analysis and conclusion is flawed. As far as I know, most approvals are for Indian generics which might just be very attractive for Federal and State Heath Aurthorities and their budgetray constraints and of course Insurers.

You are no village idiot - totally agree !

Prof- the possibility to which you refer has been the subject of prior speculation. The two reported Asian Pharma's that were looking at Recordati back in August 2016 (pre UK launch) may well of come across Fortacin as part of their due diligence. My thinking would be that it they saw commercial opportunity, particularly in Asia, they could very easily have aquired shares post the UK launch once the EMA approval was protected. I don't think it would have anything to do with strenghening the value of Recordati, which if reports are correct is already very highly valued, perhaps too highly. The obvious question is if there is a potential suitor, why are they holding fire- my only repsonse to that is that they are waiting for the FDA approval and might concerns that an Asian or Chinese Pharma will be put to the back of the queue by the FDA. Clearly the motivation not to disclose crossing the 5% threshhold and others thereafter is huge- a pharma taking a 5% stake would trigger takeover speculation and the share price would rocket sky high. All very speculative though.

Piltick - I should send the tampers to Jabber and once used onto the Mousetrap - that should result in a rich supply of green hydrogen for some time to come! Is a CEO stating that his company will be in the Footsie 100 within 4 years acceptable ?

In your fantasy world - you just don't get it which is amply demonstrated by your refernce to Waste2Tricity as a supplier. Waste2Tricity has no track record of ever producing any income, it has a balance sheet of straw and shares 2 common directors with Phe, Ryan and KA. Its not a vote of confidence, merely a company playing with itself amongst chums and screwing Phe hareholders in the process who give up 50% of future profits - although that day will never come.

Guilty as charged- its not Bingo on a Friday night its Charades - silly me !

Jabber- before you strat throwing stones in glass houses you need to get your facts right. The deal with Waste2Tricity was struck in Jan 2017, it is now mid May 2018 that is almost 18 months. so some time ago ago. As for presisitent shorting being the cause of Phe's share price collapse that is absolute unfounded nonsense, incorrect and knowigly misleading to others as you tyry and save your Friday night Bingo money. AIM stock short positions are published weekly. Phe has nver been on that list, repeat Phe has never been on that list. The reason for Phe's share price collapse is purely down to the wider invetment community having no confidence or belief that it will ever deliver a commercially viable unit.

lt74- the deal to take shares was struck in Jan 2017, it is not a new development or vote of confidence. It was a deal between Waste2Tricity and Phe who both share common directors in KA and Ryan.

Bignose - I guess everyone has a price and a time to bid arrivederci. It ws back in August 2016 that it was reported that two Asian pharma's were looking at bidding for Recordati. I am not sure about close door discussions and whilst Dr Mike may have some influence I suspect any interested party will independently and with their own advisers formulate their own assumptions and sales projections. If an undisclosed stake has been taken I suspect it is without RP's knowledge. I guess the question is would an Asian pharma be quite happy to stick 2 fingers up at the HKEX, afterall it would save them millions- could you imagine how the share price would react to the disclosure of a 5% stake by a Asian pharma.

Bignose- link below, apparently Recordati been up sale for last couple of years, CVC Partners were lloking at it, but have pulled out for the moment due to the political uncertainty in Italy. You may recall that there were also a couple of Asian pharma's reported as looking at buying Recordati. https://www.bloomberg.com/news/articles/2014-11-28/plethora-in-license-talks-for-drug-to-rival-viagra-sales

Plethora Solutions expects offers from at least six pharma companies to licence a drug in the US for premature ejaculation, according to the company founder, who helped develop and market Pfizer�s Viagra, Bloomberg reports. Discussions are approaching term-sheet stage with three of the international drug makers, which sell sexual health or testosterone-replacement products, said Michael Wyllie, the company�s CSO. A licensing agreement will probably be reached before the company submits the drug, called Fortacin, to US regulators late next year, he said. Fortacin uses the same active ingredients as AstraZeneca�s Emla cream, an anaesthetic that is used off-label for premature ejaculation, Wyllie said. Anti-depressants such as Zoloft and Prozac are also used for the same purpose, given their sexual dysfunction side effects, suggesting a large unmet need, he said. �This could be as big as Viagra,� Wyllie said in an interview in London today. �I�d be surprised if we had not decided on an agreement by this time next year.� Plethora is also open to offers to acquire the company outright, he said. The company�s shares rose six per cent to 6.6 pence in London, paring the decline this year to 48 per cent. Plethora has no products on the market and is valued at GBP45 million ($70 million). Fortacin was approved by European regulators in November 2013. It�s not for sale yet as Plethora awaits approval for a six-dose canister that the company plans to market for EUR50 ($62) to EUR60, Wyllie said. The drug will be available by prescription only, which will secure its branding image and higher price compared with OTC products, he said.